Sebastiano Buti
A5013913173- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Bladder and Urothelial Cancer Treatments
- Diabetes Treatment and Management
- Renal and related cancers
- Economic and Financial Impacts of Cancer
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Neutropenia and Cancer Infections
- Inflammatory Biomarkers in Disease Prognosis
- Urinary and Genital Oncology Studies
- Ferroptosis and cancer prognosis
- Cancer Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Metabolism, Diabetes, and Cancer
- Prostate Cancer Treatment and Research
- Cancer, Lipids, and Metabolism
- Gastric Cancer Management and Outcomes
- Immune cells in cancer
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
University of Parma
2016-2025
University Hospitals Parma Medical Center
2016-2024
Ospedale di Parma
2012-2023
Italian Oncology Group of Clinical Research
2022-2023
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2017-2023
University of Bologna
2019
University of L'Aquila
2019
Policlinico S.Orsola-Malpighi
2019
Creative Research Enterprises (United States)
2017
Istituti Ospitalieri di Cremona
2006-2015
<h3>Background</h3> Recent evidence suggested a potential correlation between overweight and the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. <h3>Patients methods</h3> We conducted retrospective study advanced patients consecutively treated with anti-PD-1/PD-L1 inhibitors, order to compare clinical outcomes according baseline BMI levels as primary analysis. Based on their BMI, were categorized into overweight/obese (≥ 25) non-overweight (< 25). A gender analysis was...
Inflammation indexes and body mass index (BMI) are easily evaluated, predict survival, potentially modifiable. We evaluated the potential association of inflammatory BMI with clinical outcome patients renal cell carcinoma (RCC) undergoing immune checkpoint inhibitor therapy.A prospective cohort metastatic RCC treated nivolumab enrolled in Italian Expanded Access Program from July 2015 through April 2016 was examined. Reference measures inflammation were identified for...
Abstract Background Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials immune checkpoint inhibitors. Materials and Methods Consecutive patients advanced cancer, treated anti-programmed death-1 (PD-1) agents, were evaluated according to the presence pre-existing AIDs. The incidence immune-related adverse events (irAEs) outcomes compared among subgroups. Results A total 751 enrolled; median age was 69 years. Primary tumors as follows:...
Geriatric (aged ≥80 years) patients are historically underrepresented in cancer clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) geriatric patients. These agents associated with immune-related adverse events (irAEs), which may be particularly morbidity this population.To provide insight into outcomes and safety ICIs among cancer.A Multicenter, international retrospective study 928 different tumors treated single-agent between 2010 to 2019 from 18...
Background: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior regulatory approval.Methods: Pts previously treated advanced or mRCC were eligible receive nivolumab 3 mg/kg every 2 weeks.Pts included in the analysis had received ≥1 dose of and monitored drug-related adverse events (drAEs) using CTCAE v.4.0.Immune-related (ir) AEs defined as displaying a certain,...
Background The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression. Methods We present the analysis according to baseline body mass index (BMI) BMI variation a large cohort metastatic NSCLC with expression ≥50%, first line pembrolizumab. also evaluated control treated platinum-based...
Background: Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC) patients achieve a long-term benefit from immunotherapy. Moreover, identification of prognostic biomarkers is still an unmet clinical need. Methods: This multicenter retrospective study investigated role peripheral-blood inflammatory indices and factors to develop novel score in mRCC receiving at least second-line nivolumab. The complete blood count before first cycle therapy was assessed by...
Metastatic collecting duct carcinoma (mCDC) is a rare type of non-clear cell renal (ncRCC) with poor prognosis and no standard treatments. Despite retrospective series that have documented the benefit cabozantinib in ncRCC, prospective trials evaluated this treatment mCDC.To determine whether an active patients mCDC.The caBozantinib cOllectiNg ductS Renal Cell cArcInoma (BONSAI) trial was open-label, single-arm, phase 2 clinical carried out between January 2018 November 2020 at single...
Background: First-line therapies based on immune-checkpoint inhibitors (ICIs) significantly improved survival of metastatic renal cell carcinoma (mRCC) patients. Cabozantinib was shown to target kinases involved in immune-escape and prolong patients pre-treated with tyrosine-kinase-inhibitors (TKIs). The impact ICIs combinations first line subsequent is still unclear. Methods: This an open label, multicenter, single arm, phase II study designed assess activity, safety efficacy cabozantinib...
Abstract Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large cohort of ICI recipients treated at 21 institutions June 2014 2020, we studied on glucose-lowering medications (GLM) for T2DM had shorter overall survival (OS) and progression-free (PFS). We used targeted transcriptomics subset explore differences the tumor microenvironment (TME) or...
Abstract Background Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with receiving immune checkpoint inhibitors. Methods This retrospective study included locally advanced or metastatic inhibitors between 2015 2022 across 24 centers in the United States, Europe, Asia. Overall survival progression-free were estimated using Kaplan-Meier method. Objective response rates determined per Response...
Abstract Background Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations standard therapy in all mRCC patients regardless International Metastatic RCC Database Consortium (IMDC) risk category, even though TKI monotherapy is still a option selected patients. However, comparisons between strategies lacking and few real-world data this setting. For reason, regimen choice represents an important issue...